title: [Clinical studies on ciprofloxacin in chronic respiratory tract infection].
abstract: Ciprofloxacin (CPFX), a new pyridone carboxylic acid, was administered orally to the patients with chronic respiratory tract infection and its clinical efficacy and safety were studied in a multicenter open trial. The results and summarized as follows. 1. The efficacy rate for the patients with acute exacerbation as 52.5% (21/40) in 2 week-treatment, and 75.0% (24/32) in 4 week-treatment. 2. The efficacy rate for the patients with chronic phase was 23.1% (6/26) in 2 week-treatment, and 26.9% (7/26) in 4 week-treatment, but acute exacerbation was not observed in any of the patients. 3. CPFX was administered to 6 patients over 60 days for the prophylaxis of acute exacerbation. Only 2 patients had acute exacerbation in 2 and 3 months after the start of the therapy, respectively. 4. Bacteriological eradication rate was high except P. aeruginosa, for which the eradication rate was about 20%. 5. Side effects were observed in 3 patients, and abnormal findings of laboratory tests were observed in 5 patients, though they were not severe. These results show that CPFX is a useful antimicrobial agent for the treatment of chronic respiratory tract infections.
authors.affiliation: 2nd Department of Internal Medicine, School of Medicine, Fukuoka University.
authors.forename: M
authors.initials: M
authors.lastname: Yoshida
authors.forename: K
authors.initials: K
authors.lastname: Watanabe
authors.forename: N
authors.initials: N
authors.lastname: Tamaru
authors.forename: T
authors.initials: T
authors.lastname: Ishibashi
authors.forename: M
authors.initials: M
authors.lastname: Takamoto
authors.forename: H
authors.initials: H
authors.lastname: Yamada
authors.forename: O
authors.initials: O
authors.lastname: Katoh
authors.forename: T
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: M
authors.initials: M
authors.lastname: Ando
authors.forename: M
authors.initials: M
authors.lastname: Matsumoto
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*
chemical_list: D002939:Ciprofloxacin